Abstract:The intricate relationship between mitogen-activated protein kinase 3 (MKK3) and MYC proto-oncogene protein (MYC) activation holds deep implications for the progression of cancer, particularly in the context of triple negative breast cancer (TNBC). Despite significant progress, the challenge of discovering effective MYC-targeted drugs persists, demanding innovative approaches to control MYC-dependent malignancies. A promising avenue in this pursuit involves disrupting the protein-protein interactions (PPIs) between MKK3 and MYC. The significance of this interaction is emphasized by the activation of MYC by MKK3 in diverse cell types, presenting a novel perspective for therapeutic interventions in MYC-driven pathways. In the current study, a novel in silico strategy to screen small molecule libraries that target the MKK3-MYC interaction was conducted. Dynamic structure-based pharmacophore models were developed and utilized for screening the small molecule libraries, enabling the identification of compounds exhibiting favorable alignment with the defined pharmacophore features. Subsequently, physics-based simulations approaches were conducted on these selected hit molecules. Steered molecular dynamics (sMD) simulations were utilized to assess the correlation between the necessary forces to dissociate candidate hit ligands from the binding pocket and their corresponding average binding free energies (MM/GBSA). Comparative analysis of the average binding free energies of the identified hits obtained from the small molecule libraries represent that the identified compounds have promising predicted binding affinities compared to the reference molecule SGI-1027. Therefore, these findings may signify a crucial advancement in our ability to control MYC activation in cancer.

Developing Dynamic Structure‐Based Pharmacophore and ML‐Trained QSAR Models for the Discovery of Novel Resistance‐Free RET Tyrosine Kinase Inhibitors

Cheminformatics-based identification of phosphorylated RET tyrosine kinase inhibitors for human cancer

Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors

Structural Optimization and Structure-Activity Relationship Studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine Derivatives As a New Class of Inhibitors of RET and Its Drug Resistance Mutants.

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose

Pharmacophore Modeling and Virtual Screening to Identify Potential RET Kinase Inhibitors.

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase

Discovery of Potent, Orally Active Compounds of Tyrosine Kinase and Serine/Threonine-Protein Kinase Inhibitor with Anti-Tumor Activity in Preclinical Assays

Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation

1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1h-pyrazole-4-carboxamide Derivatives As New Rearranged During Transfection (RET) Kinase Inhibitors Capable of Suppressing Resistant Mutants in Solvent-Front Regions

Can New Structure of RET Inhibitors Capable of Suppressing Resistant in Non-Small-Cell Lung Cancer?

Progress and Challenges in RET-targeted Cancer Therapy

Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

Generating Potential RET-Specific Inhibitors Using a Novel LSTM Encoder–Decoder Model

Discovery of 4-Methyl-n-(4-((4-methylpiperazin- 1-Yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1h-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide As a Potent Inhibitor of RET and Its Gatekeeper Mutant

Employing Steered MD Simulations for Effective Virtual Screening: Active Pharmacophore Search by Dynamic Corrections to target MKK3-MYC Interactions

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform

Mutant anaplastic lymphoma kinase inhibitor identification by integrated in silico approaches

Design of novel anti-cancer drugs targeting TRKs inhibitors based 3D QSAR, molecular docking and molecular dynamics simulation

Discovery of 4-Chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides As Novel RET Kinase Inhibitors